Kingworld Medicines Group (HKSE:01110) Total Liabilities : HK$698 Mil (As of Dec. 2023)

View and export this data going back to 2000. Start your Free Trial

What is Kingworld Medicines Group Total Liabilities?

Kingworld Medicines Group's Total Liabilities for the quarter that ended in Dec. 2023 was HK$698 Mil.

Kingworld Medicines Group's quarterly Total Liabilities increased from Dec. 2022 (HK$635.58 Mil) to Jun. 2023 (HK$669.15 Mil) and increased from Jun. 2023 (HK$669.15 Mil) to Dec. 2023 (HK$698.16 Mil).

Kingworld Medicines Group's annual Total Liabilities increased from Dec. 2021 (HK$603.90 Mil) to Dec. 2022 (HK$635.58 Mil) and increased from Dec. 2022 (HK$635.58 Mil) to Dec. 2023 (HK$698.16 Mil).

Kingworld Medicines Group Total Liabilities Historical Data

The historical data trend for Kingworld Medicines Group's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kingworld Medicines Group Total Liabilities Chart

Kingworld Medicines Group Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

675.64

683.83

603.90

635.58

698.16

Kingworld Medicines Group Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Total Liabilities	Get a 7-Day Free Trial															603.90	617.02	635.58	669.15	698.16

Kingworld Medicines Group Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Kingworld Medicines Group's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	507.002	+	(171.064	+	20.091
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	698

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	1463.093	-	764.936
	=	698

Kingworld Medicines Group's Total Liabilities for the quarter that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	507.002	+	(171.064	+	20.091
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	698

Total Liabilities	=	Total Assets (Q: Dec. 2023 )	-	Total Equity (Q: Dec. 2023 )
	=	1463.093	-	764.936
	=	698

Kingworld Medicines Group Total Liabilities Related Terms

Thank you for viewing the detailed overview of Kingworld Medicines Group's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Kingworld Medicines Group (HKSE:01110) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Kingworld Medicines Group Ltd (HKSE:01110) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

198 Daxin Road, 8th-9th Floor, Block A, Majialong Chuangxin Building, Nanshan District, Guangdong Province, Shenzhen, CHN, 518016

Website

https://www.kingworld.com.cn

Kingworld Medicines Group Ltd is engaged in Distribution sales of pharmaceutical and healthcare products such as branded imported pharmaceutical and healthcare products primarily in Hong Kong and the PRC, and Manufacturing and sales of electrotherapeutic and physiotherapeutic devices and general medical examination devices primarily carried out in the PRC. It derives the majority of its revenue from Distribution sales of pharmaceutical and healthcare products segment.

Executives

Chan Lok San	2101 Beneficial owner
Zhao Li Sheng	2101 Beneficial owner
Sinopharm Capital Limited	2201 Interest of corporation controlled by you
Sinopharm Healthcare Fund L.p.	2101 Beneficial owner
Sun Hill Capital Investments Limited	2201 Interest of corporation controlled by you
Wu Aimin	2201 Interest of corporation controlled by you
Sun Hill Capital Investments Limited	2201 Interest of corporation controlled by you
Wu Aimin	2201 Interest of corporation controlled by you

Kingworld Medicines Group (HKSE:01110) Headlines

No Headlines